Minority patients less likely to have amyloid plaques necessary for Alzheimer’s treatments

Fewer Black, Hispanic and Asian patients meet biomarker qualifications for landmark treatments that may slow the progression of Alzheimer’s disease by targeting amyloid plaques, according to new findings published in JAMA Neurology.